Investing.com -- AstraZeneca PLC (LSE:LON: AZN ) said on Tuesday that Imfinzi, its bladder cancer treatment, has been recommended in the European Union.
The pharmaceutical company further stated that Imfinzi has been well tolerated and no new safety signals have been detected.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.